Skip to main content
SpringerLink
Log in

Monoclonal Antibodies as Therapeutic Agents

  • Chapter
  • First Online:
Immunopharmacology

  • 856 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 69.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 89.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Bibliography

  • Albanell J, Codony J, Rovira A, Mellado B, et al. 2003. Mechanism of action of anti-HER2 monoclonal antibodies: Scientific update on trastuzumab and 2C4. Adv Exp Med Biol. 532:253–268.

    PubMed  CAS  Google Scholar 

  • Baca M, Presta LG, O’Connor SJ, Wells JA. 1997. Antibody humanization using monovalent phage display. J Biol Chem. 272:10678–10684.

    PubMed  CAS  Google Scholar 

  • Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, et al. 2007. Clinical response to adalimumab: Relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis. 66:921–926.

    PubMed  CAS  Google Scholar 

  • Bennett JM, Kaminski MS, Leonard JP, Vase JM, et al. 2005. Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and Iodine I 131 tositumomab. Blood. 1052: 4576–4582.

    Google Scholar 

  • Bielekova B, Richert N, Howard T, Blevins G, et al. 2004. Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc Natl Acad Sci. 101:8705–8708.

    Google Scholar 

  • Binder M, Otto F, Mertelsmann R, Veelken H, et al. 2006. The epitope recognized by rituximab. Blood. 108:1975–1978.

    PubMed  CAS  Google Scholar 

  • Bonner JA, Harari PM, Giralt J, Azarmia N, et al. 2006. Radiotherapy plus centuximab for squamous-cell carcinoma of the head and neck. NEJM. 354:567–578.

    PubMed  CAS  Google Scholar 

  • Bordigoni P, Dimicoli S, Clement L, Baumann C. 2006. Daclizumab, an efficient treatment for steroid-refractory acute graft-versus-host disease. Br J Hematol. 135:382–385.

    CAS  Google Scholar 

  • Borro JM, De-la-Torre M, Miguelez C, Fernandez R, et al. 2005. Comparative study of basiliximab treatment in lung transplantation. Transplant Proc. 37:3996–3998.

    Google Scholar 

  • Boulianne GL, Hozumi N, Shulman MJ. 1984. Production of functional chimeric mouse/human antibody. Nature. 312:643–646.

    PubMed  CAS  Google Scholar 

  • Boyne J, Elter T, Engert A. 2003. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. 14:520–535.

    Google Scholar 

  • Braendstrup P, Bjerrum OW, Nielsen OJ, Jensen BA, et al. 2005. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura. Am J Hematol. 78:275–280.

    PubMed  CAS  Google Scholar 

  • Brennan DC, Daller JA, Lake KD, Cibrik D. 2006. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. NEJM. 355:1967–1977.

    PubMed  CAS  Google Scholar 

  • Bruggemann M, Witner G, Waldmann H, Neuberger MS. 1989. The immunogenicity of chimeric antibodies. J Exp Med. 170:2153–2157.

    PubMed  CAS  Google Scholar 

  • Burton C, Kaczmarski R, Jan-Mohamed R. 2003. Interstitial pneumonitis related to rituximab therapy. NEJM. 348:2690–2691.

    PubMed  Google Scholar 

  • Carter P, Presta L, Gorman CM, Ridgway JB, et al. 1992. Humanization of anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA. 89:4285–4289.

    Google Scholar 

  • Carter PJ. 2006. Potent antibody therapeutics by design. Nat Rev Immunol. 6:343–357.

    PubMed  CAS  Google Scholar 

  • Cartron G, Watier H, Golay J, Solal-Celigny P. 2004. From bench to the bedside: Ways to improve rituximab efficacy. Blood. 104:2635–2642.

    PubMed  CAS  Google Scholar 

  • Chothia C, Lesk AM, Tramontano A, Levitt M, et al. 1989. Conformations of immunoglobulin hypervariable regions. Nature. 342:877–883.

    PubMed  CAS  Google Scholar 

  • Choy EH, Pnaayi GS. 2001. Cytokine pathways and joint inflammation in rheumatoid arthritis. NEJM. 344:907–916.

    PubMed  CAS  Google Scholar 

  • Clark M. 2000. Antibody humanization: A case of the “emperor’s new clothes?” Immunol. Today. 21:397–402.

    CAS  Google Scholar 

  • Coiffier B, Lepage E, Briere J, Herbrecht R, et al. 2002. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. NEJM. 346:235–242.

    PubMed  CAS  Google Scholar 

  • Connors JM. 2005. Radioimmunotherapy – hot new treatment for lymphoma. NEJM. 352: 496–498.

    PubMed  CAS  Google Scholar 

  • Cosimi AB, Burton RD, Colvin RB, Goldstein G. 1981. Treatment of cute renal allograft rejection with OKT3 monoclonal antibody. Transplantation. 32:535–539.

    PubMed  CAS  Google Scholar 

  • Cunningham D, Humblet Y, ,Siena S, Khayat D, et al. 2004. Centuximab monotherapy and centuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. NEJM. 351: 337–345.

    PubMed  CAS  Google Scholar 

  • Davies AJ, Rohatiner AZ, Howell S, Britton KE, et al. 2004. Tositumomab and Iodine I 131 tositumomab for recurrent indolent and transformed B cell non-Hodgkin’s lymphoma. J Clin Oncol. 22:1469–1479.

    PubMed  CAS  Google Scholar 

  • Davis TA, White CA, Grillo-Lopez AJ, Velasquez WS, et al. 1999. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin’s lymphoma: Results of a phase II trial of Rituximab. J Clin Onc. 17:1851–1857.

    CAS  Google Scholar 

  • Dedrick RL, Walicke P, Garovoy M. 2002. Anti-adhesion antibodies efalizumab, a humanized anti-CD11a monoclonal antibody. Transplant Immunol. 9:181–186.

    CAS  Google Scholar 

  • Edwards J, Szczepanski L, Szechinski J, Filipowicz-Sosnowaska A, et al. 2004. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. NEJM. 350:2572–2581.

    PubMed  CAS  Google Scholar 

  • Ettenger RB, Marik J, Rosenthal JT, Fine RN, et al. 1988. OKT3 for rejection reversal in pediatric renal transplantation. Clin Transplant. 2:180–184.

    Google Scholar 

  • Foote J, Winter G. 1992. Antibody framework residues affecting the conformation of the hypervariable loops. J Mol biol. 224:487–499.

    PubMed  CAS  Google Scholar 

  • Francis RJ, Sharma SK, Springer C, Green AJ, et al. 2002. A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours. Br J Cancer. 87:600–607.

    PubMed  CAS  Google Scholar 

  • Gaston RS, Deierhoi MH, Patterson T, Prasthofer E, et al. 1991. OKT3 first-dose reaction: Association with T cell subsets and cytokine release. Kid Internat. 39:141–148.

    CAS  Google Scholar 

  • Goldberg RM. 2006. Therapy for metastatic colorectal cancer. The Oncologist. 11:981–987.

    PubMed  CAS  Google Scholar 

  • Goldman M, Abramowicz D, DePauw L, Alelgre M, et al. 1989. OKT3-induced cytokine released attenuation by high-dose methylprednisolone. Lancet. 2:802–803.

    PubMed  CAS  Google Scholar 

  • Goldstein G, Fuccello AJ, Norman DJ, Sheild CF, et al. 1986. OKT3 monoclonal antibody plasma levels during therapy and the subsequent development of host antibodies to OKT3. Transplantation. 42:507–511.

    PubMed  CAS  Google Scholar 

  • Goncalves LF, Ribeiro AR, Berdichevski R, Joelsons G. 2007. Basiliximab improves graft survival in renal transplant recipients with delayed graft function. Transplant Proc. 39:437–438.

    Google Scholar 

  • Graves JE, Nunley K, Heffernan MP. 2007. Off-label uses of biologics in dermatology: Rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab and alefacept. J Am Acad Dermatol. 56:e55–e79.

    PubMed  Google Scholar 

  • Griggen JG. 2007. How I treat indolent lymphoma. Blood. 109:4617–4626.

    Google Scholar 

  • Hale G, Dyer MJS, Clark MR, Phillips JM, et al. 1988. Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1 H. Lancet. 2:1394–1399.

    PubMed  CAS  Google Scholar 

  • Hericourt J, Richet CH. 1895. de la serotherapie dans la traitement du cancer, Physologie Pathologique. 120:567–569.

    Google Scholar 

  • Hershberger RE, Randall SC, Eisen HJ, Bergh C-H, et al. 2005. Daclizumab to prevent rejection after cardiac transplantation. NEJM. 352:2705–2713.

    PubMed  CAS  Google Scholar 

  • Himmelweit F. 1960. The Collected Papers of Paul Erlich, Vol. 3,59, Pergmon, London.

    Google Scholar 

  • Hoogenboom HR. 2005. Selecting and screening recombinant antibody libraries. Nat Biotech. 23:1117–1125.

    Google Scholar 

  • Hooks MA, Wade CS, Millikan WJ. 1991. Muromonab CD-3: A review of its pharmacology, pharmacokinetics, and clinical use in transplantation. Pharmacotherapy. 11:26–37.

    PubMed  CAS  Google Scholar 

  • Hortobagyi GN. 2005. Trastuzumab in the treatment of breast cancer. NEJM. 353:1734–1736.

    PubMed  CAS  Google Scholar 

  • Hosenpud JD. 2005. Immunosuppression in cardiac transplantation. NEJM. 352:2749–2750.

    PubMed  CAS  Google Scholar 

  • Hudis CA. 2007. Trastuzumab-mechanism of action and use in clinical practice. NEJM. 357:39–51.

    PubMed  CAS  Google Scholar 

  • Hudson PJ, Souriau C. 1992. Engineered antibodies. Nat Med. 9:129–134.

    Google Scholar 

  • Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, et al. 2004. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. NEJM. 350:2335–2342.

    PubMed  CAS  Google Scholar 

  • Janeway C, Travers P, Walport M, Schlomchik M. 2001. Immunobiology, Fifth Edition, Garland Science, New York and London.

    Google Scholar 

  • Jazirehi AR, Bonavida B. 2005. Cellular and molecular signal transduction pathways modulated by rituximab (Rituxan, anti-CD20 mab) in non-Hodgkin’s lymphoma: Implications in characterization of therapeutic intervention. Oncogene. 24:2121–2143.

    PubMed  CAS  Google Scholar 

  • Jensen M, Klehr M, Vogel A, Schmitz S, et al. 2007. One step generation of fully chimeric antibodies using C gamma 1 and C kappa mutant mice. J Immunother. 30:338–349.

    PubMed  CAS  Google Scholar 

  • Jones PT, Dear PH, Foote J, Neuberger MS, et al. 1986. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature. 321:522–525.

    PubMed  CAS  Google Scholar 

  • Kaminski MS, Tuck M, Estes J, Kolstad A, et al. 2005. 131I-Tositumomab therapy as initial treatment for follicular lymphoma. NEJM. 352:441–449.

    PubMed  CAS  Google Scholar 

  • Kapic E, Becic F, Kusturica J. 2004. Basiliximab, mechanism of action and pharmacological properties. Med Arch. 58:373–376.

    Google Scholar 

  • King DJ, Adair JR, Angal S, Low DC, et al. 1992. Expression, purification and characterization of a mouse-human chimeric antibody and chimeric Fab fragment. Biochem J. 281:317–323.

    PubMed  CAS  Google Scholar 

  • Knight DM, Trinh H, Le J, Siegel S, et al. 1993. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol. 30:1443–1453.

    PubMed  CAS  Google Scholar 

  • Kohler G, Milstein C. 1975. Continuous culture of fused cells secreting antibody of predefined specificity. Nature. 256:495–497.

    PubMed  CAS  Google Scholar 

  • Krauss WC, park JW, Kirpotin DB, Hong K, Benz CC. 2002. Emerging antibody-based HER2 (ErbB-2/neu) therapeutics. Breast Dis. 11:113–124.

    Google Scholar 

  • Leahy MF, Seymour JF, Hicks RJ, Turner JH. 2006. Multicenter phase II clinical study of Iodine-131-Rituximab radiotherapy in relapsed or refractory indolent non-Hodgkin’s lymphoma. J Clin Oncol. 24:4418–4425.

    PubMed  CAS  Google Scholar 

  • Lind P, Lechner P, Hausmann B. 1991. Development of human anti-mouse antibodies (HAMA) after single and repeated diagnostic application of intact murine monoclonal antibodies. Antibody Immunoconjug Radiopharm. 4:811–818.

    Google Scholar 

  • Littlejohns P. 2006. Trastuzumab for early breast cancer: Evolution or revolution? Lancet Oncol. 7:22–23.

    PubMed  Google Scholar 

  • Lo-Coco F, Cimino G, Breccia M, Noguera NI, et al. 2004. Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. Blood. 104: 1995–1999.

    PubMed  CAS  Google Scholar 

  • Mascelli MA, Zhou H, Sweet R, Getsy J, et al. 2007. Molecular, biologic and pharmacokinetic properties of monoclonal antibodies: Impact of these parameters on early clinical development. J Clin Pharmacol. 47:553–565.

    PubMed  CAS  Google Scholar 

  • McArthur HL, Chia S. 2007. Cardiotoxicity of trastuzumab in clinical practice. NEJM. 357:94–95.

    PubMed  CAS  Google Scholar 

  • McCune SL, Gockerman JP, Rizzieri DA. 2001. Monoclonal antibody therapy in the treatment of non-Hodgkin’s lymphoma. JAMA. 286:1149–1152.

    PubMed  CAS  Google Scholar 

  • McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, et al. 1998. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol. 16:2825–2833.

    PubMed  CAS  Google Scholar 

  • Menter A, Leonardi CL, Sterry W, Bos JD. 2006. Long-term management of plaque psoriasis with continuous efalizumab therapy. J Am Acad Dermatol. 54:S182–S188.

    PubMed  Google Scholar 

  • Morris JA, Hanson JE, Steffen BJ, Chu AH, et al. 2005. Daclizumab is associated with decreased rejection and improved patient survival in renal transplant patients. Clin Transplant. 19:340–345.

    PubMed  CAS  Google Scholar 

  • Morrison SL, Johnson MJ, Herzenberg LA, Oi VT. 1984. Chimeric human antibody molecules: Mouse antigen binding domains with human constant region domains. Proc Natl Acad Sci USA. 81:6851–6855.

    Google Scholar 

  • Nadler LM, Stashenko P, Hardy R, Kaplan WB, et al. 1980. Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma associated antigen. Cancer Res. 40:3147–3154.

    PubMed  CAS  Google Scholar 

  • O’Dell JR. 2004. Therapeutic strategies for rheumatoid arthritis. NEJM. 350:2591–2602.

    PubMed  Google Scholar 

  • Okamoto H. 2006. Effect of rituximab in refractory SLE: Inhibition of Th1. Rheumatology. 45:121–122.

    PubMed  CAS  Google Scholar 

  • Olsen NJ, Stein CM 2004. New drugs for rheumatoid arthritis. NEJM. 350:2167–2179.

    PubMed  CAS  Google Scholar 

  • Ortho Multicenter Transplant Study Group. 1985. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. NEJM. 313:337–342.

    Google Scholar 

  • Pegram M, Hsu S, Lewis G, Pietras R. 1999. Inhibitory effects of combination of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancer. Oncogene. 18:2241–2251.

    PubMed  CAS  Google Scholar 

  • Pendley C, Schantz A, Wagner C. 2003. Immunogenicity of therapeutic monoclonal antibodies. Curr Opin Mol Ther. 5:172–179.

    PubMed  CAS  Google Scholar 

  • Penichet ML, Morrison SL. 2004. Designing and engineering human forms of monoclonal antibodies. Drug Deve Res. 61:121–136.

    CAS  Google Scholar 

  • Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, et al. 2005. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. NEJM. 353:1659–1672.

    PubMed  CAS  Google Scholar 

  • Piccoli R, Olson KA, Vallee BL, Fett JW. 1998. Chimeric anti-angiogenin antibody cAb 26-2F inhibits the formation of human breast cancer xenograft in athymic mice. PNAS USA. 95:4579–4583.

    PubMed  CAS  Google Scholar 

  • Posner MR, Wirth LJ. 2006. Centuximab and radiotherapy for head and neck cancer. NEJM. 354:634–636.

    PubMed  CAS  Google Scholar 

  • Present D, Rutgeerts P, Targan S, Hanauer S, et al. 1999. Infliximab for the treatment of fistulas in patients with Crohn’s disease. NEJM. 340:1398–1405.

    PubMed  CAS  Google Scholar 

  • Presta LG, Lahr SJ, Shields RI, Porter JP, et al. 1993. Humanization of an antibody directed against IgE J Immunol. 151:2623–2632.

    PubMed  CAS  Google Scholar 

  • Przepiorka D, Kernan NA, Ipppoliti C, Papandopoulas EB, et al. 2000. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for the treatment of acute graft-versus-host disease Blood. 2000:83–89.

    Google Scholar 

  • Queen C, Schneider WP, Selick HE, Payne PW, et al. 1989. A humanized antibody that binds to the interleukin 2 receptors. PNAS USA. 86:10029–10033.

    PubMed  CAS  Google Scholar 

  • Rai KR, Freter CD, Mercier RJ, Cooper MR. 2002. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received Fludarabine. J Clin Oncol. 20:3891–3897.

    PubMed  CAS  Google Scholar 

  • Ramirez CB, Marino IR. 2007. The role of basiliximab induction therapy in organ transplantation. Expert Opin Biol Ther. 7:137–148.

    PubMed  CAS  Google Scholar 

  • Rawstron AC, Kennedy B, Moreton P, Dickinson AJ, et al. 2004. Early prediction of outcome and response to alemtuzumab therapy in chronic lymphocytic leukemia. Blood. 103:2027–2031.

    PubMed  CAS  Google Scholar 

  • Riechmann L, Clark M, Waldmann H, Winter G. 1988. Reshaping human antibodies for therapy. Nature. 332:323–327.

    PubMed  CAS  Google Scholar 

  • Ritz J, Schlossman SF. 1982. Utilization of monoclonal antibodies in the treatment of leukemia and lymphoma. Blood. 59:1–11.

    PubMed  CAS  Google Scholar 

  • Roskos LK, Davis CG, Schwag GM. 2004. The clinical pharmacology of therapeutic monoclonal antibodies. Drug Dev Res. 61:108–120.

    CAS  Google Scholar 

  • Rutgeerts P, Sanborn WJ, Feagan BG, Reinisch W, et al. 2005. Infliximab for induction and maintenance therapy for ulcerative colitis. NEJM. 353:2462–2476.

    PubMed  CAS  Google Scholar 

  • St. Clair EW. 2002. Infliximab treatment for rheumatic disease. Clinical and radiological efficacy. Ann Rehum Dis. 61:ii67–ii69.

    Google Scholar 

  • Sands B, Anderson F, Bernstein C, Chey W, et al. 2004. Infliximab maintenance therapy for fistulizing Crohn’s disease. NEJM. 350:876–885.

    PubMed  CAS  Google Scholar 

  • Scheinberg DA, Chapman BA. 1995. In: Birch JR, Lennox ES, Eds. Monoclonal Antibodies: Principles and Applications, Wiley-Liss, New York, pp. 45–105.

    Google Scholar 

  • Schmidt-Hieber M, Fietz T, Knauf W, Uharek L. 2005. Efficacy of the interleukin-2 receptor antagonist basiliximab in steroid refractory graft-versus-host disease. Br J Hemtaol. 130:568–574.

    CAS  Google Scholar 

  • Schmitz U, Versmold A, Kaufmann P, Frank HG. 2000. Phage display: A molecular tool for the generation of antibodies – a review. Placenta. 21:S106–S112.

    PubMed  Google Scholar 

  • Schrag D. 2004. The price tag on progress – chemotherapy for colorectal cancer. NEJM. 351:317–319.

    PubMed  CAS  Google Scholar 

  • Schroeder TJ, Michael AT, First MR, Hariharan S, et al. 1994. Variations in serum OKT3 concentration based upon age, sex, transplanted organ, treatment regimen and anti-OKT3 status. Ther Drug Monit. 16:361–367.

    PubMed  CAS  Google Scholar 

  • Sfikakis PP. 2002. Behcet’s disease: A new target for anti-tumour necrosis factor treatment. Ann Rheum Dis. 61:ii51–ii56.

    PubMed  Google Scholar 

  • Sharkey RM, GHoodenberg DM. 2006. Targeted therapy of cancer: New prospects for antibodies and immuno conjugates. CA Cancer J Clin. 56:226–243.

    PubMed  Google Scholar 

  • Shields CJ, Winter DC, Becker JM, Prushik SG, et al. 2006. Infliximab for ulcerative colitis. NEJM. 354:1424–1426.

    PubMed  CAS  Google Scholar 

  • Shimoni A, Zwas ST, Oksman Y, Hardan I, et al. 2007. Yttrium-90-ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin’s lymphoma. Exp Hematol. 35:534–540.

    PubMed  CAS  Google Scholar 

  • Smith I, Procter M, Gelber RD, Guillaume S, et al. 2007. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomized controlled trial. Lancet. 369:29–36.

    PubMed  CAS  Google Scholar 

  • Song H, Du Y, Sgouros G, Prideaux A, et al. 2007. Therapeutic potential of 90Y and 131I-labeled anti-CD20 monoclonal antibody in treating non-Hodgkin’s lymphoma with pulmonary involvement. JNM. 48:150–157.

    PubMed  Google Scholar 

  • Stern M, Herrmann R. 2005. Overview of monoclonal antibodies in cancer therapy: Present and promise. Crit Rev Oncol Hematol. 54:11–29.

    PubMed  CAS  Google Scholar 

  • Tan P, Mitchell DA, Buss TN, Holmes MA, et al. 2002. Super humanized antibodies: Reduction of immunogenic potential by complementarity-determining region grafting with human germline sequences: Application to an anti-CD28. J Immunol. 169:1119–1125.

    PubMed  CAS  Google Scholar 

  • Topol EJ, Moliterno DJ, Hermann HC, Powers ER, et al. 2001. Comparison of two platelet glycoproteins IIb/IIIa inhibitors, Tirofiban and abciximab, for the prevention of ischemic events with precutaneous coronary revascularization. NEJM. 344:1888–1894.

    PubMed  CAS  Google Scholar 

  • Valabrega G, Montemurro F, Aglietta M. 2007. Trastuzumab: Mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol. 18:977–984.

    PubMed  CAS  Google Scholar 

  • Verbeek WHM, Mulder CJJ, Zweegman S, Vivas S, et al. 2006. Alemtuzumab for refractory celiac disease. NEJM. 355:1396–1397.

    PubMed  CAS  Google Scholar 

  • Verhoeyen M, Milstein C, Winter G. 1988. Reshaping human antibodies: Grafting an antilysozyme activity. Science. 239:1534–1536.

    PubMed  CAS  Google Scholar 

  • Vincenti F, Kirkman R, Light S, Bumgardner G, et al. 1998. Interleuin-2 receptor blockade with daclizumab to prevent acute rejection in renal transplantation. NEJM. 338:161–165.

    PubMed  CAS  Google Scholar 

  • Vivas S, Morales JM, Ramos F, Suarez-Vilela D. 2006. Alemtuzumab for refractory celiac disease in a patient at risk for enteropathy-associated T-cell lymphoma. NEJM. 354:23–24.

    Google Scholar 

  • Waldmann T.A. 1991. Monoclonal antibodies in diagnosis and treatment. Science. 252:1657–1662.

    PubMed  CAS  Google Scholar 

  • Waldmann TA, Levy R, Coller BS. 2000. Emerging therapies: Spectrum of applications of monoclonal antibody therapy. Hematology. 2000:394–408.

    Google Scholar 

  • Waldmann TA. 2003. Immunotherapy: Past, present and future. Nat Med. 9:269–277.

    PubMed  CAS  Google Scholar 

  • Waldmann TA. 2007. Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases and the prevention of allograft rejection: A 25-year personal odyssey. J Clin Immunol. 27:1–18.

    PubMed  CAS  Google Scholar 

  • Wellington K, Perry CM. 2005. Efalizumab. Am J clin Dermatol. 6:113–118.

    PubMed  Google Scholar 

  • White CA. 2004. Radioimmunotherapy in non-Hodgkin’s lymphoma: Focus on 90Y-ibritumonomab tiuxetan (Zevalin). J Exp Ther Oncol. 4:305–316.

    PubMed  CAS  Google Scholar 

  • Wiseman GA, Witzig, TE. 2005. Yttrium-90 (90Y) ibritumonomab tiuxetan (Zevalin) induces long-term durable responses in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma. Cancer Biother Radiopharm. 20:185–188.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Creighton University Medical Center, Omaha, NE, USA

    Manzoor M. Khan Ph.D.

Authors
  1. Manzoor M. Khan Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Manzoor M. Khan Ph.D. .

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Khan, M.M. (2008). Monoclonal Antibodies as Therapeutic Agents. In: Immunopharmacology. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-77976-8_5

Download citation

Publish with us

Policies and ethics

Search

Navigation